Table 1.
Baseline Patient Characteristics.
| Before PSM |
After PSM |
|||||
|---|---|---|---|---|---|---|
| TEER without Cancer N = 1767 |
TEER with Cancer N = 513 |
Standardized difference | TEER without Cancer N = 503 |
TEER with Cancer N = 503 |
Standardized difference | |
| Baseline Characteristics | ||||||
| Age | 75.3 ± 11.4 years | 77.80 ± 9.5 years | 0.24 | 77.7 ± 9.9 years | 77.7 ± 9.6 years | 0.006 |
| Male | 942 (53.3 %) | 287 (55.9 %) | 0.29 | 275 (54.7 %) | 279 (58.5 %) | 0.01 |
| White | 1426 (80.7 %) | 448 (87.3 %) | 0.18 | 422 (83.9 %) | 438 (87.1 %) | 0.03 |
| Black | 167 (9.5 %) | 35 (6.8 %) | 0.09 | 40 (8.0 %) | 35 (7 %) | 0.03 |
| Hispanic | 100 (5.7 %) | 12 (2.7 %) | 0.14 | 13 (2.6 %) | 14 (2.8 %) | 0.01 |
| Co-Morbid Conditions | ||||||
| Hyperlipidemia | 1157 (65.5 %) | 374 (72.9 %) | 0.16 | 359 (71.4 %) | 2365 (72.6 %) | 0.02 |
| Hypertension | 1387 (78.5 %) | 457 (89.1 %) | 0.29 | 435 (86.5 %) | 447 (88.9 %) | 0.07 |
| Ischemic heart diseases | 1255 (71.0 %) | 3406 (79.1 %) | 0.18 | 390 (77.5 %) | 397 (78.9 %) | 0.03 |
| Atrial fibrillation and flutter | 1103 (62.4 %) | 361 (70.4 %) | 0.16 | 342 (68.0 %) | 353 (70.2 %) | 0.04 |
| Cardiomyopathy | 537 (30.4 %) | 200 (39.0 %) | 0.18 | 194 (38.6 %) | 192 (38.2 %) | 0.008 |
| Diabetes mellitus | 531 (30.1 %) | 200 (39.0 %) | 0.03 | 146 (29.0 %) | 158 (31.4 %) | 0.05 |
| Laboratory Data | ||||||
| Creatinine | 1.5 ± 1.3 | 1.4 ± 0.8 | 0.11 | 1.5 ± 1.2 | 1.4 ± 0.8 | 0.03 |
| Hemoglobin | 11.20 ± 2.4 | 11.1 ± 2.3 | 0.01 | 11.3 ± 2.3 | 11.2 ± 2.3 | 0.04 |
| Sodium | 138.5 ± 3.7 | 138.8 ± 3.8 | 0.06 | 138.6 ± 3.6 | 138.7 ± 3.8 | 0.03 |
| Platelets | 185.2 ± 69.0 | 187.7 ± 74.8 | 0.03 | 185.3 ± 68.7 | 187.7 ± 74.7 | 0.03 |
| LDL | 78.6 ± 32.8 | 81.4 ± 36.1 | 0.08 | 79.4 ± 33.00 | 81.8 ± 35.9 | 0.07 |
| Hemoglobin A1c | 6.1 ± 1.4 | 6.1 ± 1.5 | 0.03 | 6.1 ± 1.4 | 6.1 ± 1.5 | 0.04 |
| BMI | 27.3 ± 6.2 | 26.2 ± 6.4 | 0.17 | 27.2 ± 5.9 | 26.3 ± 6.3 | 0.15 |
| LVEF ≤ 40 % | 148 (8.4 %) | 70 (13.6 %) | 0.16 | 64 (12.7 %) | 61 (12.1 %) | 0.01 |
| NYHA Classification | 2.6 ± 0.7 | 2.8 ± 0.5 | 0.21 | 2.8 ± 0.6 | 2.8 ± 0.5 | 0.01 |
| Medications | ||||||
| Diuretics | 1413 (80.0 %) | 445(86.7 %) | 0.18 | 437 (86.9 %) | 435 (86.50 %) | 0.01 |
| Beta-Blockers | 1373 (77.7 %) | 435 (84.8 %) | 0.18 | 414 (82.3 %) | 425 (84.5 %) | 0.05 |
| Aspirin | 1343 (76.0 %) | 423 (82.5 %) | 0.16 | 402 (79.9 %) | 413 (82.1 %) | 0.05 |
| Anti-lipemic drugs | 1153 (65.3 %) | 357 (69.6 %) | 0.09 | 355 (70.60 %) | 348 (69.20 %) | 0.03 |
| Clopidogrel | 894 (50.6 %) | 264 (51.5 %) | 0.01 | 274(54.50 %) | 258 (51.30 %) | 0.06 |
| Ticagrelor | 77 (4.4 %) | 16 (3.1 %) | 0.06 | 23 (4.6 %) | 15 (3.00 %) | 0.08 |
| Prasugrel | 21 (1.2 %) | 10 (1.9 %) | 0.06 | 10 (2.0 %) | 10 (2.0 %) | <0.001 |
| ACE Inhibitors | 699 (39.6 %) | 240 (46.8 %) | 0.14 | 228 (45.3 %) | 232 (46.1 %) | 0.01 |
| Angiotensin II Inhibitors | 560 (31.7 %) | 152 (29.6 %) | 0.04 | 138 (27.4 %) | 150 (29.8 %) | 0.05 |
| Sacubitril | 154 (8.7 %) | 37 (7.2 %) | 0.05 | 32 (6.40 %) | 37 (7.4 %) | 0.03 |
| Anticoagulants | 1538 (87.0 %) | 480 (93.6 %) | 0.22 | 468 (93.0 %) | 470 (93.4 %) | 0.01 |
Demonstrates the baseline characteristics of the patients who underwent TEER in those without a malignancy history and those with a malignancy history. Patient characteristics are compared between two cohorts (No malignancy vs malignancy) before and after propensity score matching.
Abbreviations: ACE inhibitors, angiotensin converting enzyme inhibitors, ARB, Aldosterone receptor blockers, AF, Atrial fibrillation, BMI, Body Mass Index, CKD, Chronic kidney disease, HBA1c, Hemoglobin A1c, LDL, Low Density Lipoprotein, LVEF, Left Ventricular Ejection Fraction.